A practical reference on lyophilized powder: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-20 and is reviewed periodically as new material appears.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
== Risk factors == The mechanism of injury for NAION used to be quite controversial. However, experts in the field have come to a consensus that most cases involve two main risk factors. The first is a predisposition in the form of a type of optic disc shape. The optic disc is where the axons from the retinal ganglion cells collect into the optic nerve. The optic nerve is the bundle of axons that carry the visual signals from the eye to the brain. This optic nerve must penetrate through the wall of the eye, and the hole to accommodate this is usually 20-30% larger than the nerve diameter. In some patients the optic nerve is nearly as large as the opening in the back of the eye, and the optic disc appears "crowded" when seen by ophthalmoscopy. A crowded disc is also referred to as a "disc at risk". While a risk factor, the vast majority of individuals with crowded discs do not experience NAION. The second major risk factor involves more general cardiovascular risk factors. The most common are diabetes, hypertension and high cholesterol levels. While these factors predispose a patient to develop NAION, the most common precipitating factor is marked fall of blood pressure during sleep (nocturnal arterial hypotension)- that is why at least 75% of the patients first discover visual loss first on waking from sleep. When other risk factors for NAION are present, taking blood pressure medications at night should be avoided as this can exacerbate nighttime hypotension. Beta blockers in particular are associated with increased incidence of NAION.
== D == Dendrite A branched projection of a neuron that receives synaptic input from other neurons and transmits electrical signals toward the cell body. Dendritic spine A small, membranous protrusion from a neuron's dendrite that typically receives input from a single synapse of an axon. Spines are key sites for synaptic strength and plasticity. Depolarization A change in membrane potential that makes the interior of a neuron more positive relative to the outside, often initiating an action potential if a threshold is reached. Descending neuron A neuron that originates in the brain or brainstem and projects downward through the spinal cord to influence motor circuits and autonomic function. Descending neurons are critical for voluntary movement, postural control, and reflex modulation. Major descending pathways include the corticospinal, reticulospinal, rubrospinal, and vestibulospinal tracts. Developmental neuroscience A branch of neuroscience focused on how the nervous system develops from embryonic stages through adulthood, including neurogenesis, synaptogenesis, and pruning. Diffusion tensor imaging (DTI) A form of magnetic resonance imaging that maps the diffusion of water molecules in brain tissue to visualize white matter tracts and structural connectivity. Diencephalon A region of the forebrain that includes structures such as the thalamus and hypothalamus. It plays a role in sensory relay, autonomic function, and endocrine regulation.
== Legacy == After the end of the Cold War in 1991, the assets of the USSR's space program passed mainly to Russia. Since then, the United States and Russia have cooperated in space with the Shuttle-Mir Program, and the International Space Station (ISS). The Russians continue to use their R-7 rocket family as their orbital workhorse to launch the Soyuz crewed spacecraft and its Progress derivative uncrewed cargo craft as shuttles to the ISS. After the 2011 retirement of the Space Shuttle, American crews were dependent on the R-7–Soyuz to reach the ISS, until the 2020 first flight of the US Crew Dragon Commercial Crew Development vehicle. In 2023 the Russian Federation resumed the Luna missions as a part of the Luna-Glob programme with the launch of Luna 25 (47 years after the Soviet Luna 24), amidst American reignition of interest in the Moon with the Artemis program beginning with the launch of Artemis I in 2022. Some of this competitiveness is part of the New Space Race.
Industry, constituting 19.74% of GDP and 24% of total employment, is the second-largest sector. Large-scale manufacturing (LSM) dominates, representing 12.2% of GDP, with cement production thriving due to demand from Afghanistan and the domestic real estate sector. In 2013, Pakistan exported 7,708,557 metric tons of cement, with an installed capacity of 44,768,250 metric tons. The textile industry, a key player in Pakistan's manufacturing, contributes 9.5% to GDP and employs around 15 million people. As of 2022, Pakistan ranks seventh globally in cotton production, with substantial spinning capacity, making it a major exporter of textile products in Asia. China has been a significant buyer of Pakistani textiles, importing US$1.527 billion worth of textiles in 2012.
=== High blood potassium === Calcium gluconate is used as a cardioprotective agent in people with high blood potassium levels, with one alternative being the use of calcium chloride. It is recommended when the potassium levels are high (>6.5 mmol/L) or when the electrocardiogram (ECG) shows changes due to high blood potassium. Though it does not have an effect on potassium levels in the blood, it reduces the excitability of cardiomyocytes, thereby lowering the likelihood of cardiac arrhythmias.
Sources: en.wikipedia.org
== Early life == Lamont Bentley was born in Milwaukee, Wisconsin on October 25, 1973, the son of Donald Gardison and Loyce Bentley. Lamont grew up on Milwaukee's north side of town and attended Webster Middle School. He moved to Los Angeles with his mother, who wished to pursue a career as a professional singer.
=== Dry infusion === Dry infusion is the combination of partial dehydration and osmotic dehydration using a humectant. The food product is first dehydrated and then the resultant product is added to a humectant solution to reach the desired water activity. This method is desirable because it results in a higher quality and more appealing product. However, more energy is used for this method because it is two processing steps combined. Dry infusion is primarily employed by the U.S military and NASA for production of IMF to produce safe, palatable food that can be consumed much later than it is produced.
=== Pharmacology === Preclinical and early clinical pharmacology studies characterized insulin icodec as a basal insulin analogue. The molecular modifications were intended to create an albumin-bound circulating depot, while preserving insulin receptor-mediated metabolic activity and limiting mitogenic activity relative to human insulin.
(WINNER) The contestant won the whole competition. ‡ The contestant won the Pre-Heat challenge. (WIN) The contestant won the Main Heat challenge. (HIGH) The contestant had one of the best dishes for that week. (IN) The contestant performed well enough to move on to the next week. (LOW) The contestant had one of the bottom dishes for that week, but was not eliminated. (OUT) The contestant was eliminated for worst dish. (WDR) The contestant voluntarily left the competition.
Sources: en.wikipedia.org
The Gβγ subunit is essential for the formation of heterotrimeric G protein through its association with the Gα subunit allowing the G proteins coupling to the GPCR. Therefore, any agent inhibiting the Gβγ subunits signalling effects must not interfere with the heterotrimeric G protein formation or Gα subunit signalling. Gβγ expression is universal throughout almost all the cells of the body so any agent acting to inhibit this subunit could elicit numerous side effects. Small molecule inhibitors that target the coupling of Gβγ to specific effectors and do not interfere with normal G protein cycling/ heterotrimeric formation, have the potential to work as therapeutic agents in treating some specific diseases.
extensive property A physical quantity whose value is proportional to the size of the system it describes or to the quantity of matter in the system. Examples include mass, volume, enthalpy, and entropy. Contrast intensive property.
The United States entered World War I alongside the Allies in 1917 helping to turn the tide against the Central Powers. In 1920, a constitutional amendment granted nationwide women's suffrage. During the 1920s and 1930s, radio for mass communication and early television transformed communications nationwide. The Wall Street Crash of 1929 had triggered the Great Depression, to which President Franklin D. Roosevelt responded with the New Deal plan of "reform, recovery and relief", a series of unprecedented and sweeping recovery programs and employment relief projects combined with financial reforms and regulations. During the 1930s, severe drought and dust storms caused or exacerbated by poor agricultural practices forced hundreds of thousands of displaced farming families (often called "Okies" because many originated from Oklahoma) to migrate from the Great Plains to California in search of subsistence. Initially neutral during World War II, the U.S. began supplying war materiel to the Allies of World War II in March 1941 and entered the war in December after Japan's attack on Pearl Harbor. Agreeing to a "Europe first" policy, the U.S. concentrated its wartime efforts on Japan's allies Italy and Germany until their final defeat in May 1945. The U.S. developed the first nuclear weapons and used them against the Japanese cities of Hiroshima and Nagasaki in August 1945, which historians consider central to the end of World War II in Asia.
National Accrediting Agency for Clinical Laboratory Sciences (NAACLS) is a US based educational accreditation organization that accredits clinical laboratory educational programs. NAACLS is accredited by the Council for Higher Education Accreditation (CHEA). NAACLS is the primary accrediting body for clinical laboratory programs in the US, though the Accrediting Bureau of Health Education Schools(ABHES) also accredits a handful of programs. Graduates of the ABHES are not eligible for the American Society for Clinical Pathology(ASCP) certification, but are eligible for the American Medical Technologists(AMT) certification. NAACLS has criticized the rise of non-accredited, on-the-job training (OJT) programs as undermining the laboratory profession.
== Overdose == Glucagon, used in the treatment of overdose, increases the strength of heart contractions, increases intracellular cAMP, and decreases renal vascular resistance. It is, therefore, useful in patients with beta blocker cardiotoxicity. Cardiac pacing is usually reserved for patients unresponsive to pharmacological therapy. People experiencing bronchospasm due to the β2 receptor-blocking effects of nonselective beta blockers may be treated with anticholinergic drugs, such as ipratropium, which are safer than beta agonists in patients with cardiovascular disease. Other antidotes for beta blocker poisoning are salbutamol and isoprenaline.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.